Publications by authors named "K Groen"

Claim this Profile
U
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.
Kazimierz Groen, Febe Smits, Kazem Nasserinejad, Mark-David Levin, Josien C Regelink

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.
Wassilis S C Bruins, Febe Smits, Carolien Duetz, Kaz Groen, Charlotte L B M Korst

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.
Febe Smits, Kaz Groen, Mark-David Levin, Claudia A M Stege, Roel van Kampen

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.
M R Seefat, D G J Cucchi, L van Boven, N Durdu-Rayman, K Groen

Br J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.
Wassilis S C Bruins, Febe Smits, Carolien Duetz, Kazem Nasserinejad, Kazimierz Groen

Hemasphere· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis